12,673 Shares in AbbVie Inc. $ABBV Acquired by Financial Planning Hawaii Inc.

Financial Planning Hawaii Inc. bought a new stake in AbbVie Inc. (NYSE:ABBV) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 12,673 shares of the company’s stock, valued at approximately $2,896,000. AbbVie makes up about 1.7% of Financial Planning Hawaii Inc.’s investment portfolio, making the stock its 13th biggest position.

Several other hedge funds have also bought and sold shares of ABBV. Brighton Jones LLC raised its position in shares of AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock valued at $4,072,000 after buying an additional 3,401 shares in the last quarter. Revolve Wealth Partners LLC grew its position in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Schnieders Capital Management LLC. grew its position in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after acquiring an additional 789 shares in the last quarter. Grantham Mayo Van Otterloo & Co. LLC increased its stake in AbbVie by 16.1% in the second quarter. Grantham Mayo Van Otterloo & Co. LLC now owns 6,792 shares of the company’s stock valued at $1,261,000 after acquiring an additional 940 shares during the last quarter. Finally, Loomis Sayles & Co. L P increased its stake in AbbVie by 53.7% in the second quarter. Loomis Sayles & Co. L P now owns 53,995 shares of the company’s stock valued at $10,023,000 after acquiring an additional 18,866 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors.

Insider Activity

In other AbbVie news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. This trade represents a 66.34% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of AbbVie stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the sale, the executive vice president owned 38,137 shares in the company, valued at approximately $8,771,510. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.08% of the stock is owned by company insiders.

Analysts Set New Price Targets

ABBV has been the subject of several research analyst reports. Piper Sandler lifted their price target on AbbVie from $289.00 to $299.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 18th. UBS Group reduced their price objective on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Citigroup cut their target price on AbbVie from $235.00 to $230.00 and set a “neutral” rating for the company in a research note on Tuesday, January 27th. Finally, Wall Street Zen upgraded shares of AbbVie from a “buy” rating to a “strong-buy” rating in a research report on Saturday, February 28th. Two analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.15.

AbbVie Price Performance

Shares of ABBV stock opened at $213.12 on Tuesday. The business has a 50-day moving average of $221.93 and a 200 day moving average of $224.66. AbbVie Inc. has a 1-year low of $164.39 and a 1-year high of $244.81. The stock has a market capitalization of $376.83 billion, a PE ratio of 90.30, a P/E/G ratio of 0.73 and a beta of 0.34.

AbbVie (NYSE:ABBV) last issued its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. The firm had revenue of $16.62 billion for the quarter, compared to analysts’ expectations of $16.39 billion. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned $2.16 earnings per share. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Wednesday, April 15th. AbbVie’s dividend payout ratio is currently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.